In Brief

Shareholder suit against Johnson & Johnson, including CFO Caruso, may proceed; Novartis pauses OTC production at Nebraska plant; Mead Johnson finds Enfamil powder clear of bacteria after stores pull the product; John Gay leaves NPA after two years as executive director and CEO; more news In Brief.

A class action complaint alleging securities fraud at Johnson & Johnson is permitted to proceed against Colleen Goggins, former chairman of the firm’s worldwide consumer group, and current Chief Financial Officer Dominic Caruso – and by virtue of those defendants, against J&J as well – a federal judge says Dec. 19. Judge Freda Wolfson of the U.S. District Court for the District of New Jersey granted J&J’s motion to dismiss with respect to CEO William Weldon and Consumer Healthcare President Peter Luther, noting the plaintiffs had failed to prove allegations that Weldon and Luther misrepresented their awareness of OTC quality control problems and a “phantom recall” of Motrin. Wolfson says it appears “plausible” that Goggins knew of the phantom recall despite telling a congressional committee she did not, and finds Caruso may have made misleading statements during an investor call. As part of a separate suit, a J&J special committee found organizational changes, but not individual executives, at fault for the QC problems that led to extensive OTC recalls Also see "J&J Directors Find Root Causes But Little Blame For OTC Quality Issues" - Pink Sheet, 25 July, 2011..

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

Vertex’s Alyftrek For CF Among Six Orphans On Track For Pan-EU Approval

 

The European Medicines Agency has recommended 16 drugs for EU-wide approval, including Vertex’s cystic fibrosis drug Alyftrek and five other orphans.

EMA’s Role In Regulatory Reliance For Post-Approval Changes

 
• By 

The European Medicines Agency’s assessments of applications for variations play a key role in supporting international regulatory reliance mechanisms. Companies can aid this by ensuring the scope of their post-approval changes is clear, and notifying the EMA when sharing reports with non-EU regulators.

Semaglutide For MASH Among Raft Of New EU Filings

 

Novo Nordisk’s application seeking EU marketing approval to use its GLP-1 receptor agonist to treat cirrhotic metabolic dysfunction-associated steatohepatitis is one of 15 new drug filings the European Medicines Agency has started reviewing. Meanwhile, Arrowhead’s filing for its familial chylomicronemia syndrome, plozasiran, is being fast tracked.

More from Geography